07.17.08 –
GAAP Basic and Diluted Net Income of $0.03 Per Share, Reflecting One Time Expenses
Non-GAAP Basic and Diluted Net Income of $0.38 and $0.35 Per Share, Respectively
Earnings Conference Call & Webcast Today (With Slides) at 5:00 p.m. EDT
Cubist to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
07.02.08 –
- Leverages Proven U.S. Acute Care Sales Organization
- Complements Cubist's Gram-Positive CUBICIN
- Complements Cubist's Gram-Positive CUBICIN
Cubist Testifies on Need to Encourage Antibiotic Research and Development
06.24.08 –
Antimicrobial Resistance Reaching "Crisis Point"
stories:
Cubist Pharmaceuticals (NASDAQ: CBST) is a biopharmaceutical company focused on developing and commercializing antiinfective therapies for the acute care environment. The men and women of Cubist, some who are pictured on our web site, are part of an organization that is determined to take on the challenges associated with providing new antimicrobial therapies to combat the "super bugs". The information on these pages will tell you more about our success to date and our plans for the future.
| Last | 22.03 |
|---|---|
| Change |  0.20 |
| % Change | 0.90% |
| Bid | N/A |
| Bid Size | N/A |
| Ask | 23.88 |
Quotes Delayed At Least 20 Minutes
Cubist Investor Relations »
Next Earnings Call Information »
